We serve tris(8-methylnonyl) benzene-1,2,4-tricarboxylate CAS:36631-30-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | Colorless to light yellow liquid | Conform |
| Saponification value, mg/kg |
235-245 | 238 |
| Hydroxyl value, mgKOH/g |
≤10 | 5 |
| Iodine value, mgI2/100g |
≤10 | 1 |
| APHA | ≤100 | 60 |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like tris(8-methylnonyl) benzene-1,2,4-tricarboxylate、 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Triisodecyl trimellitate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Triisodecyl trimellitate Use and application,Triisodecyl trimellitate technical grade,usp/ep/jp grade.
Related News: The program caused the price of some drugs to plunge more than 90% when it was introduced last year in some cities, state news agency Xinhua said.N-[4-(6-methyl-benzothiazol-2-yl)-phenyl]-phthalamic acid manufacturer The program caused the price of some drugs to plunge more than 90% when it was introduced last year in some cities, state news agency Xinhua said.N-[[2′-[[(3,4-Dimethyl-5-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1′-biphenyl]-2-yl]methyl]-N-methyl-1-phenylcyclopropanecarboxamide supplier As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations. hexahydro-2a,4a,7a-triaza-cyclopenta(cd)indene vendor The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.
